Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) enjoyed a 61.11% run-up in share price since hitting record low of $3.6. The stock managed 3.57% rise and now stands at $5.8 as of 3/14/2019. At a recent session, the prices were hovering between $5.62 and $5.95. This company shares are 537.93% off its target price of $37 and the current market capitalization stands at $59.91M. The recent change has given its price a 10.38% lead over SMA 50 and -73.39% deficit over its 52-week high. The stock witnessed 30.34% gains, -5.68% declines and -25.57% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CATB’s volatility during a week at 6.66% and during a month it has been found around 5.51%.Catabasis Pharmaceuticals, Inc. (CATB) Top Holders
Institutional investors currently hold around $15 million or 22.6% in CATB stock. Look at its top three institutional owners: Federated Investors Inc /Pa/ owns $5.84 million in Catabasis Pharmaceuticals, Inc., which represents roughly 9.75% of the company’s market cap and approximately 38.95% of the institutional ownership. Similar statistics are true for the second largest owner, Samsara Biocapital, Llc, which owns 300,000 shares of the stock are valued at $1.68 million. The third largest holder is Sv Health Investors, Llc, which currently holds $1.6 million worth of this stock and that ownership represents nearly 2.67% of its market capitalization.Catabasis Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 9 institutional holders increased their position in Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) by some 616,868 shares, 21 decreased positions by 318,601 and 6 held positions by 1,663,400. That puts total institutional holdings at 2,598,869 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 552,471 shares while 12 institutional investors sold out their entire positions totaling 127,261 shares.Catabasis Pharmaceuticals, Inc. (CATB) Analyst Guide
Several analysts have released their opinion on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation [T1].